Received: 30 April 2021
Accepted: 11 August 2021
First Online: 21 October 2021
: The study was approved by the Royan Institute Ethics Board (NO: 98000030). Each patient completed a questionnaire pertaining to general health issues and medical history information as routinely done at the Isfahan Fertility and Infertility Center (Isfahan, Iran).
: All authors contributed to the study. They have all seen the final version and consent to its submission.
: Collectively, the authors do not declare any competing interests. For the sake of transparency, PG, AM, JRD and RJA are respectively CEO, director and scientific advisors of a US-based biotechnology company (Celloxess LLC, Ewing, NJ, USA) that contributes to preventative medicine with a focus on the production of antioxidant dietary supplements. Celloxess LLC did not contribute in any way to this study.